Learn how Pfizer’s clinical research aims to help advance the treatment of prostate cancer.

Pfizer continues to strive for potential treatment options that may offer new hope for men with prostate cancer. As with many potential treatments, our goal is to help prevent the cancer from advancing further and to improve life expectancy.

We are evaluating study medicines in clinical trials that focus mostly on advanced types of prostate cancer, such as castration-sensitive or castration-resistant prostate cancer. (Learn more about these types of prostate cancer at the bottom of the page.) These studies are researching a study medicine taken along with a currently available standard treatment.

If you or a loved one are considering taking part in a prostate cancer clinical trial, find more information below.

Refine your search

Find a prostate cancer clinical trial

    You can refine your search by selecting “Advanced filters”
    Location
      Status
      Sex
      Age

      Advanced filters

      We found 7 clinical trials

      Prostate Cancer
      150 miles
      Recruiting
      Not yet recruiting
      3 trials recruiting
      MEVPRO Prostate Cancer Clinical Trials
      Clinical trials exploring mevrometostat as a potential treatment for metastatic prostate cancer.
      • Prostate Cancer
      • Recruiting
      Recruiting
      This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
      • Prostate Cancer
      • Recruiting
      NCT07028853
      Sex: Male
      Age: 18+
      Locations: 38
      View study
      Recruiting
      A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).
      • Prostate Cancer
      • Recruiting
      NCT06551324
      Sex: Male
      Age: 18+
      Locations: 241
      View study
      Recruiting
      A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
      • Prostate Cancer
      • Recruiting
      NCT06629779
      Sex: Male
      Age: 18+
      Locations: 228
      View study
      Recruiting
      Mevrometostat Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
      • Prostate Cancer
      • Recruiting
      NCT03460977
      Sex: All
      Age: 18+
      Locations: 84
      View study
      Recruiting
      Study of PF-07248144 in Advanced or Metastatic Solid Tumors
      • Prostate Cancer
      • Recruiting
      NCT04606446
      Sex: All
      Age: 18+
      Locations: 41
      View study
      Recruiting
      A Study to Learn About Two Medicines (Apalutamide and Enzalutamide) in People With Metastatic Castration-sensitive Prostate Cancer (mCSPC)
      • Prostate Cancer
      • Recruiting
      NCT07086651
      Sex: Male
      Age: 18+
      Locations: 1
      View study
      Dec 01, 2025 - Planned start date (Not yet recruiting)
      Physician- and Patient-based Barriers to NGS Testing
      • Prostate Cancer
      • Not yet recruiting
      NCT07209176
      Sex: Male
      Age: 18+
      Locations: 0
      View study
      Show more

      About prostate cancer

      Prostate cancer occurs when the cells within the prostate gland start to multiply out of control. It is the second most common cancer in American men, after skin cancer.

      When prostate cancer has not spread beyond the prostate, treatment may first involve surgery or radiation to remove the cancer. Initial treatment may also involve medication that aims to keep levels of the male sex hormones low. This is because prostate cancer growth is often driven by male sex hormones, including testosterone.

      Metastatic castration sensitive prostate cancer occurs when the cancer spreads to other parts of the body, or if the cancer is first diagnosed when it has already spread. This type of prostate cancer is still responsive to hormone therapy.

      If hormone therapy no longer stops or slows the cancer, the condition is known as metastatic castration resistant prostate cancer.